Navigation Links
Van Andel Research Institute finding could lead to reduced side effects in anti-cancer antibiotics
Date:6/28/2011

Grand Rapids, Mich. (June 28, 2011) Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

One particularly promising anti-cancer antibiotic is Geldanamycin and a modified form of this drug known as 17AAG. Despite its proven ability to selectively kill many different forms of cancer in laboratory studies, the use of these drugs is limited due to side effects, mainly liver failure, in patients.

Newly published results from Van Andel Research Institute (VARI) researchers have determined how the anti-cancer antibiotic Geldanamycin and its derivative 17AAG work in more detail and have uncovered a possible explanation for side effects observed in clinical trials of the drug.

"The article provides novel and significant information about the clinical potential of these compounds in cancer therapy," said Yale School of Medicine Professor and Chair of Pharmacology Joseph Schlessinger, Ph.D.

Although there was much preclinical interest in the antibiotic Geldanamycin as an anti-cancer drug, it turned out to be a poor candidate for clinical trials because of its toxicity. Derivatives such as 17AAG were developed to decrease toxicity and are still being evaluated in clinical trials.

VARI researchers determined how Geldanamycin and 17AAG work in more detail in a study published in Proceedings of the National Academy of Sciences U.S.A., which could inform future drug design, and also found a way to potentially decrease the antibiotics' toxicity.

"There was so much interest early on in Geldanamycin because it resulted in the degradation of oncoproteins, important protein targets in tumor cells," said VARI Research Scientist and lead author of the paper Qian Xie, M.D., Ph.D.

"If there is a chance of decreasing the toxicity of Geldanamycin and 17AAG, it would be a boon in the treatment of cancer," said George Vande Woude, Ph.D., head of the Laboratory of Molecular Oncology at VARI that published the study.


'/>"/>

Contact: Joe Gavan
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related medicine news :

1. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
2. Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade
3. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
4. Religion benefits traumatic brain injury victims, Wayne State University research finds
5. Leading research organizations announce top-tier journal for biomedical and life sciences
6. New Crops for the Future Research Centre -- for food and non-food uses
7. Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report
8. UH Cancer Center receives $3.58 million gift for mesothelioma research
9. New application for iPhone may support monitoring and research on Parkinsons disease
10. TGen, Tecan and ASU Biodesign Institute develop sample preparation solution for proteomic research
11. Researchers identify components of speech recognition pathway in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
(Date:6/23/2016)... June 23, 2016 Leading BioSciences Inc., ... medical conditions resulting from a breakdown of the ... Greg Doyle as chief executive officer. ... executive management team and board of directors, previously ... officer. He will provide continued leadership and strategic ...
Breaking Medicine Technology: